**4. Repurposing drugs against MDR Gram-negative bacilli**

There are currently multiple repurposing drugs in preclinical development for the treatment of infections by Gram-negative critical-priority pathogens. Few of them have been evaluated in early and late stage clinical trials. A summary of recent developments in repurposing drugs *in vitro*, in animal models and in clinical trials is presented below. The different clinical trials with repurposing drugs against these pathogens are listed in **Table 2**.
